98%
921
2 minutes
20
Background: Primary small cell carcinoma of the oesophagus (PSCCE) is a gastrointestinal tumour of rare onset. The current study was to investigate the role of a novel risk stratification system (RSS) for PSCCE.
Methods: The study included patients with PSCCE attending any of five medical institutions in China in 2008-2021, four of which served as a training set (n = 422) for construction of the RSS while the other served as a separate cohort (n = 256) for validation of the model. The RSS was established based on covariates associated with overall survival (OS) with a two-sided -value of < 0.05 in multivariable regression. Survival discrimination of RSS was assessed.
Results: In the training cohort, multivariate regression analysis revealed age, Eastern Cooperative Oncology Group score, and initial lymph node metastasis to be independent prognostic factors for OS in non-distant metastatic PESCC; concurrent hepatic metastasis was the only significant predictor of distant metastatic PESCC. Accordingly, the RSS was developed and could classify patients into four subgroups: low-risk localized disease (LLD, defined as non-distant metastasis PESCC without risk factors, n = 58); high-risk localized disease (HLD, defined as non-distant metastasis PESCC with ≥ 1 risk factor, n = 199); low-risk metastatic disease (LMD, defined as metastatic PESCC without concomitant liver metastases, n = 103); and high-risk metastatic disease (HMD, definded as metastatic disease with synchronous liver metastases, n = 63). Three-year OS rates were 52.5%, 29.5%, 14.4%, and 5.7% for LLD, HLD, LMD, and HMD, respectively. When compared with the tumor-node-metastasis (TNM) system, RSS showed a consistently superior ability to predict OS in both the training and validation cohorts.
Conclusion: The RSS is a reliable stratification model that could be used to optimize treatment for PESCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010368 | PMC |
http://dx.doi.org/10.1016/j.jncc.2025.02.003 | DOI Listing |
J Natl Cancer Cent
April 2025
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Background: Primary small cell carcinoma of the oesophagus (PSCCE) is a gastrointestinal tumour of rare onset. The current study was to investigate the role of a novel risk stratification system (RSS) for PSCCE.
Methods: The study included patients with PSCCE attending any of five medical institutions in China in 2008-2021, four of which served as a training set (n = 422) for construction of the RSS while the other served as a separate cohort (n = 256) for validation of the model.
Front Urol
January 2024
Department of Urology, University of Rostock, Rostock, Germany.
Background: Triple-drug cisplatin- and taxane-based chemotherapy is the standard treatment for metastatic penile squamous cell cancer (PeSCC), with a moderate response rate of 30% to 38%. Relapse after first-line chemotherapy has a poor prognosis and there is no established second-line treatment. Mitomycin C (MMC) is used as an effective chemotherapy in squamous cell carcinoma of other localities.
View Article and Find Full Text PDFMed J Malaysia
September 2020
Universitas Indonesia, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Department of Pathology Anatomy, Indonesia.
Primary endometrial squamous cell carcinomas (PESCC) occur sporadically. It is defined as a primary carcinoma of the endometrium composed of squamous cells of varying degrees of differentiation. A 57-year-old female patient was referred to the gynaecological clinic of Faculty of Medicine, Universitas Indonesia, Dr Cipto Mangunkusumo National Referral Hospital because of abdominal enlargement with pain.
View Article and Find Full Text PDFJ Immunother
September 2019
OncoDNA SA, Gosselies, Belgium.
Penile squamous cell carcinoma (PeSCC) is a rare tumor and advanced PeSCC is associated with poor survival due to the aggressiveness of the disease and lack of effective systemic therapies. We describe for the first time a case with advanced chemoradiation refractory PeSCC who had documented response to active immunotherapy with the immune checkpoint inhibitor, anti-programmed death-1 monoclonal antibody Nivolumab. The patient suffered from a poor prognosis human papillomavirus-negative PeSCC, with a somatic inactivation mutation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in tumor cells, and treatment with Nivolumab resulted in a partial response to therapy and significant tumor shrinkage.
View Article and Find Full Text PDFEur J Surg Oncol
January 2019
Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant.
View Article and Find Full Text PDF